MARKET

NMTR

NMTR

9 Meters Biopharma
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.120
+0.020
+1.82%
After Hours: 1.120 0 0.00% 16:59 07/28 EDT
OPEN
1.090
PREV CLOSE
1.100
HIGH
1.140
LOW
1.090
VOLUME
1.79M
TURNOVER
--
52 WEEK HIGH
2.260
52 WEEK LOW
0.4510
MARKET CAP
281.54M
P/E (TTM)
-1.6398
1D
5D
1M
3M
1Y
5Y
Arvinas (ARVN), Pfizer Team up for Breast Cancer Therapy
Zacks.com · 5d ago
Vertex (VRTX) Initiates Phase II Study on Pain Candidate
Zacks.com · 07/20 11:40
9 Meters Biopharma Acquires Anti-GIP Monoclonal Antibody For Obesity-Related Disorders
Benzinga · 07/19 13:32
9 Meters Biopharma acquires anti-GIP monoclonal antibody from Lobesity
9 Meters Biopharma (NMTR) has acquired global development rights to a proprietary and highly specific humanized monoclonal antibody (mAb), LOB-0136 (now known as NM-136) that targets glucose-dependent insulinotropic polypeptide ((GIP)),
Seekingalpha · 07/19 13:22
9 Meters Biopharma, Inc. Announces Acquisition Of Humanized Anti-GIP Monoclonal Antibody From Lobesity For $5M Upfront Payment Plus Right To Contingent Payments; $45.5M In Regulatory Milestones And $50M In Sales Milestones
- Broadens existing pipeline with a monoclonal antibody against a novel target, glucose-dependent insulinotropic polypeptide (GIP) - - First planned indication is Prader-Willi Syndrome- - IND-enabling studies ongoing
Broadens existing pipeline with a monoclonal antibody against a novel target, glucose-dependent insulinotropic polypeptide (GIP) - - First planned indication is Prader-Willi Syndrome- - IND-enabling studies ongoing · 07/19 12:37
9 Meters Biopharma, Inc. Announces the Acquisition of Humanized Anti-GIP Monoclonal Antibody from Lobesity
GIP is a hormone found in the upper small intestine that is released into the blood after food is ingested. Its concentration increases significantly with overeating, leading to higher glucose absorption and greater insulin release.
ACCESSWIRE · 07/19 12:30
9 Meters Acquires LOB-0136 Antibody from Lobesity
MT Newswires · 07/19 11:10
Thinking about buying stock in Tencent Music Entertainment, Delta Air Lines, Iterum Therapeutics, HP, or 9 Meters Biopharma?
/PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for TME, DAL, ITRM, HPQ, and NMTR.
PR Newswire - PRF · 07/12 15:30
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of NMTR. Analyze the recent business situations of 9 Meters Biopharma through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 7 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average NMTR stock price target is 4.357 with a high estimate of 6.00 and a low estimate of 3.000.
EPS
Institutional Holdings
Institutions: 93
Institutional Holdings: 75.88M
% Owned: 30.19%
Shares Outstanding: 251.37M
TypeInstitutionsShares
Increased
23
13.70M
New
44
9.37M
Decreased
11
1.15M
Sold Out
11
6.78M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+3.64%
Pharmaceuticals & Medical Research
+1.92%
Key Executives
Non-Executive Chairman/Independent Director
Mark Sirgo
President/Chief Executive Officer/Director
John Temperato
Chief Financial Officer
Edward Sitar
Independent Director
Michael Constantino
Independent Director
Lorin Johnson
Independent Director
Michael Rice
No Data
About NMTR
9 Meters Biopharma, Inc., formerly Innovate Biopharmaceuticals, Inc., is a gastrointestinal platform company. The Company is focused on developing treatments for patients with rare disorders and unmet needs. Its pipeline includes drug candidates for short bowel syndrome and celiac disease. Its pipeline includes NM-002, Larazotide, NM-003 and NM-004. NM-002 is a long-acting injectable GLP-1 analogue for short bowel syndrome (SBS). Larazotide is an orally administered, gut-restricted tight-junction regulator for celiac disease. NM-003 is a GLP-2 analogue, under orphan indication selection. NM -004 is an immunomodulator, granted pediatric orphan designation in ulcerative colitis.

Webull offers kinds of 9 Meters Biopharma Inc stock information, including NASDAQ:NMTR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NMTR stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading NMTR stock methods without spending real money on the virtual paper trading platform.